Case Report

Imaging Findings of Hepatic Ewing’s Sarcoma on Computed Tomography and Gadobenate Dimeglumine-enhanced Magnetic Resonance Imaging: A Case Report and Literature Review

Tao Lu1,2, Wenhao Yang2,3,8, Xingchao Liu2,3, Xudan Yang4, Chong Yang2,5* and Wenjia Di2,3*

1Department of Radiology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; 2Organ Transplantation Center, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; 3Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, Sichuan, China; 4Department of Pathology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Received: 2 April 2021 | Revised: 2 July 2021 | Accepted: 22 July 2021 | Published: 16 August 2021

doi: 10.14218/JCTH.2021.00129.

Abstract

Ewing’s sarcoma (ES) is a tumor that often occurs in the long bones and rarely arises from visceral organs primarily. Here, we report a case of primary hepatic ES, discuss its computed tomography (CT) and gadobenate dimeglumine-enhanced magnetic resonance imaging (MRI) features. This is the first Chinese and fifth primary hepatic ES case reported, based on a literature review. Imaging examinations showed that the tumor was solid, with necrosis and hemorrhage. Contrast-enhanced images showed that the tumor was hypervascular and especially had heterogeneous signal intensity on hepaticobiliary phase MRI images. Intratumoral vessels and vascular invasion were also present.

Citation of this article: Lu T, Yang W, Liu X, Yang X, Yang C, Di W. Imaging findings of hepatic Ewing’s sarcoma on computed tomography and gadobenate dimeglumine-enhanced magnetic resonance imaging: a case report and literature review. J Clin Transl Hepatol 2022;10(3):564–569.

Keywords: Ewing’s sarcoma; Primitive neuroectodermal tumor; CT; MRI; Literature review.

Abbreviations: AFP, alpha-fetoprotein; AST, glutamic oxaloacetic transaminase; ALT, glutamic pyruvic transaminase; CA125, cancer antigen 125; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; DWI, diffusion-weighted imaging; ES, Ewing sarcoma; EWSR1, Ewing sarcoma breakpoint region 1; FISH, fluorescence in situ hybridization; FLI-1, Friend leukemia virus integration 1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hematoxylin and eosin; ICC, intrathelial cholangiocellular carcinoma; IVC, inferior vena cava; LHV, left hepatic vein; MHV, middle hepatic vein; MRI, magnetic resonance imaging; PAS, periodic acid-Schiff; PCR, polymerase chain reaction; PECT, positron emission computerized tomography; PET, positron emission tomography; PNET, primitive neuroectodermal tumor; PV, portal vein; RHV, right hepatic vein; SI, signal intensity; T2WI, T2 weighted image; T1WI, T1 weighted image; V, virus; HCC, hepatitis C virus; HCV, hepatitis C virus; HE, hematoxylin and eosin; ICC, intrathelial cholangiocellular carcinoma; IVC, inferior vena cava; LHV, left hepatic vein; MHV, middle hepatic vein; MRI, magnetic resonance imaging; PAS, periodic acid-Schiff; PCR, polymerase chain reaction; PECT, positron emission computerized tomography; PET, positron emission tomography; PNET, primitive neuroectodermal tumor; PV, portal vein; RHV, right hepatic vein; SI, signal intensity; Syn, synuclein; T1WI, T1 weighted image; T2WI, T2 weighted image.

*Correspondence to: Wenjia Di and Chong Yang, Organ Transplantation Center, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 611731, China. ORCID: https://orcid.org/0000-0002-0060-706X (CY). Tel: +86-28-8739-3707, Fax: +86-28-8778-5585, E-mail: 510860496@qq.com (WD), yangchong@med.uestc.edu.cn (CY)

Case report

Patient information

A 27-year-old woman presented with severe epigastric pain for 20 days. The patient had an unremarkable medical and family history, and the physical examination was negative. After admission, routine laboratory examinations, including serum glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT), and bilirubin index, were normal. However, serum lactate dehydrogenase was 320 U/L (normal range: 120–250 U/L). Viral serology tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) were negative. The serum tumor biomarker test revealed that the cancer antigen 125 (CA125) level was 44.5 U/mL (normal range: 0–35 U/mL), while alpha-fetoprotein (AFP) and cancer an-

Copyright: © 2022 The Author(s). This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. *This article has been published in Journal of Clinical and Translational Hepatology at https://doi.org/10.14218/JCTH.2021.00129 and can also be viewed on the Journal’s website at http://www.jcthem.net*. 

Introduction

Ewing’s sarcoma (ES) is also known as primitive neuroectodermal tumor (PNET) because of the overlap of their genetic abnormalities. ES/PNET, together with skin tumors and atypical ES, are members of the ES tumor family.1,2 ES usually occurs in the long bones of the extremities and in the pelvic bones, and extrasosseous ES can occur in the deep soft tissue around the extremities, chest wall, retroperitoneum, and solid organs, including the pancreas, kidney, uterus, ovary, gastrointestinal tract, and other visceral organs.3–8 Primary hepatic ES is uncommon, and only four cases of this disease have been reported.6,7,9,10 Herein, we present a case of primary hepatic ES/PNET and describe the computed tomography (CT) and gadobenate dimeglumine-enhanced magnetic resonance imaging (MRI) features of the tumor, with an accompanying review of the literature.
Lu T. et al: CT and MRI findings for hepatic Ewing’s sarcoma

Tigen 19–9 (CA19-9) levels were normal. Further laboratory investigations showed slightly increased monocytes (0.650 \(10^9/L\); normal range: 0.10–0.60 \(10^9/L\)), a slightly decreased lymphocyte rate (18.1%; normal range: 20–50%), and decreased albumin (3.67 g/dL; normal range: 4–5.5 g/dL) and prealbumin (14.9 mg/dL; normal range: 16–45 mg/dL). The imaging examination, including contrast-enhanced CT, indicated a heterogeneous, solid mass with areas of necrosis measuring 9.6×9.1×10 cm in the hepatic caudate lobe. The mass showed obvious heterogeneous enhancement with multiple tortuous vessels in the arterial phase and persistent enhancement with mild dilation of distal hepatic ducts in the portal venous phase (Fig. 1). The mass extended to the portacaval space and upward to invade the second porta hepatis, including the inferior vena cava (IVC), the middle hepatic vein (MHV), and the left hepatic vein (LHV). The left branch of the portal vein (PV) was also possibly invaded. On MRI, the tumor was hypointense on the T1 weighted image (T1WI) and heterogeneously hyperintense on the T2 weighted image (T2WI), showing areas of hemorrhage and necrosis. Diffusion-weighted imaging (DWI) also showed hyperintensity. After injection of gadobenate dimeglumine, the mass showed heterogeneous signal intensity (SI) (Fig. 2). Both CT and MRI prompted suspicion of mesenchymal neoplasm, such as sarcoma, in the caudate lobe of the liver. A search for any other sites of involvement of the tumor using whole-body bone scan and positron emission tomography (PET) showed no abnormality.

Surgical procedure

A laparoscopic exploration was performed and showed the mass located in the caudate lobe, 10×11 cm in size and involving segments 2/3/5/8 of the liver, the diaphragm, second porta hepatitis, RHV, MHV, and IVC (Fig. 3). On the cut surface, the tumor was grayish red and hard, with necrosis. On microscopic examination, the tumor was composed of small blue tumor cells with necrosis. Immunohistochemical examination revealed positive expression for CD99 and NKX2.2 and weak positivity for synuclein (Syn) and Ki-67 (the positive rate was approximately 20%) (Fig. 4). Dual-color, break-apart probe fluorescence in situ hybridization (FISH) examination revealed that more than 30% of the cells (200 counted cells per slide) exhibited one yellow and one red signal, which indicated a break of the Ewing sarcoma breakpoint region 1 (EWSR1) locus (Fig. 4). These findings supported a diagnosis of localized ES arising from the liver. However, the patient refused standard postoperative chemotherapy and/or radiotherapy as adjuvant treatments. She is currently alive (3 months postoperatively) without any signs of recurrence.

Fig. 1. Contrast-enhanced CT scans of the hepatic ES. (A–B) Obvious heterogeneous enhancement with multiple serpentine neovascular (axial arterial phase). (C) Persistent enhancement with mild dilation of distal hepatic ducts (portal venous phase). (D) IVC involvement (coronal portal venous phase image). IVC, inferior vena cava.
Fig. 2. Gadobenate dimeglumine-enhanced MRI of the hepatic ES. (A) Hypointense (axial T1WI) image. (B) Heterogeneous hyperintense (axial T2WI) image. (C) Diffusion restriction in DWI. (D) IVC involvement (coronal image). T1WI, T1 weighted image; T2WI, T2 weighted image; DWI, diffusion-weighted imaging; IVC, inferior vena cava.

Fig. 3. Intraoperative findings. (A) The tumor originated from the hepatic caudate lobe. (B) The tumor was greyish red and hard, with necrosis.
A literature search was initiated to review cases of primary hepatic ES. Based on the literature review, only four prior cases of primary hepatic ES have been reported. Following the previous reports and our case presented herein, 80% of patients with ES were younger than 20 years, and all patients with hepatic ES were younger than 30 years. The clinical symptoms of ES in the liver are nonspecific, with abdominal pain being the most common. Uncommon symptoms include abdominal distention, nausea, emesis, and diarrhea (Table 1).

Discussion and conclusions

Due to the rarity of the tumor, little information on the imaging features of hepatic ES is available. Relying on CT and ultrasound findings, two previous reports only described the tumor as solid, with one report using CT to describe the tumor as a multicellular cystic mass with enhanced septa, and the other to describe an enlarged liver without a mass lesion. To the best of our knowledge, this is the first case of both CT and gadobenate dimeglumine-enhanced MRI features of ES in the liver.

In the present case, the tumor was solid, with necrosis and hemorrhage, as shown by CT and MRI imaging. The tumor also showed diffusion restriction in DWI. After enhancement, the tumor was hyper vascular, with prominent intratumoral vessels in the arterial phase and persistent enhancement to the portal venous phase and delayed phase from dynamic MRI scans. The tumor was aggressive, based on vascular invasion demonstrated by CT and MRI. On HBP, the tumor showed heterogeneous SI, which was only partly due to intratumoral hyperintensity representing intralesional hemorrhage. These findings suggested the tumor to be non-HCC or –ICC but raised a suspicion of sarcoma.

With similar clinical, immunohistochemical and cytogenetic profiles, ES and PNET are regarded as two extremes of a morphologic spectrum of the same tumor entity. ES/ PNETs are divided into two main categories, according to the cell origin and location. Central PNETs are derived from the neural tube, mainly involving the brain and spinal cord. Peripheral PNETs are derived from the neural crest and occur outside the central nervous system, often involving the sympathetic nervous system or soft tissue and bones. In children, approximately 80% of ES are found in bones and <20% in soft tissues, while in adults, >50% of ES occur in soft tissues but ES rarely affects visceral organs. When visceral involvement does occur, the most common affected organ is the kidney. The liver is a rather rare organ of involvement. The gross appearance of the tumor is usually multinodulated, soft, and friable, and it usually exceeds 10 cm in its large.

Fig. 4. Pathological and immunohistochemical staining. (A) The tumor was composed of hypercellular small, blue-colored, round cells microscopically (HE, 200×). (B) Strong positive staining for CD 99 (IHC, 200×). (C) Strong positive staining for NKX2.2 (IHC, 200×). (D) Weak positive staining for Syn (IHC, 200×). (E) Weak positive staining for Ki-67 (IHC, 200×). (F) Dual-color, break-apart probe FISH examination, showed one yellow and one red signal, which indicated a break of the EWSR1 locus. HE, hematoxylin and eosin; CD 99, Cluster of Differentiation 99; NKX2.2, NK2 homeobox 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; EWSR1, Ewing sarcoma breakpoint region 1.
Lu T. et al: CT and MRI findings for hepatic Ewing’s sarcoma

The tumors could be solid, cystic, or diffusely enlarged to involve the entire liver, but most of the tumors reported have been solid, with or without areas of necrosis and hemorrhage. Histologically, ES is composed of poorly differentiated small round cells containing dark staining and round or oval nuclei. Special stains, such as periodic acid-Schiff (PAS), usually show positivity for cytoplasmic glycogen, and immunostains usually show positivity for CD99, vimentin and NKX2.2. However, these findings are not specific to ES, so molecular biological examination is recommended to confirm the disease. FISH or real-time polymerase chain reaction (PCR) tests have demonstrated that most ES’s harbor the EWSR1-ETS fusion protein, which results in a chromosomal translocation t (11:22) between the EWS (22q12) and friend leukemia virus integration 1 (FLI-1) (11q24) genes.

The major differential diagnosis for hepatic ES includes carcinosarcoma, angiosarcoma, leiomyosarcoma, and undifferentiated embryonal sarcoma. Carcinosarcoma is a rare malignant tumor containing both carcinomatous and sarcomatous components. It is more common in elderly males, and most patients have elevated tumor markers, including CEA, AFP, and CA19-9. Tumors usually show heterogeneous density/intensity accompanied by vast cystic changes and necrosis with moderate to clearly-irregular marginal enhancement. Angiosarcoma is the most common malignant mesenchymal tumor of the liver, accounting for <2% of primary hepatic tumors. It typically occurs in males in the fifth to seventh decade of life. Tumors are multifocal and have heterogeneous signals on T2WI and HBP images with intralesional hemorrhage. On dynamic scans, angiosarcoma demonstrates at least some extent of progressive enhancement with enhancing foci of irregular or rim-like nodular/linear shape, or bizarre shapes. Hepatic leiomyosarcoma derives from smooth muscle cells in hepatic vessels, bile ducts, or ligaments. The patient ages at the time of tumor detection ranged from 5 months to 86 years, with no obvious sex difference. On CT, the tumors are hypodense, with necrosis or bleeding, and heterogeneous enhancement. On MRI, the tumors are hypointense on T1WI and heterogeneous hyperintense on T2WI with heterogeneous enhancement. Undifferentiated embryonal sarcoma of the liver occurs mostly in children aged 6 to 10 years and rarely in adults. On CT scan, the tumor appears as a solitary, well-defined cystic mass with solid nodules and septations, showing progressive enhancement. Tortuous vessels within the tumor may be observed.

The standard treatment plan for extraosseous ES has not been established and should correspond to the treatment method for all sarcomas in the Ewing family. ES/PNET is highly sensitive to chemotherapy and radiotherapy; however, surgical resection should also be considered for patients with localized extraosseous ES. In line with this, systemic multiagent chemotherapy combined with surgery and/or radiotherapy is recommended. Previous studies have shown a 5-year survival of 58–61%, with a median survival of 120 months for patients with PNETs. Finally, age and surgical treatment are recognized as important prognostic variables in the treatment of extraosseous ES, in particular.

**Funding**

None to declare.

**Conflict of interest**

The authors have no conflict of interests related to this publication.
Design of the study (TL, WY), collection of the patient's clinical data (WY, CY), analysis of the patient's clinical data and of the literature data (XY, WD, XL), and writing of the paper (TL, CY).

Ethical approval and consent for publication

The hospital board committee provided approval for the procedural application in clinic and case report publication. Written informed consent for publication was obtained from the patient.

Data sharing statement

All data generated or analyzed during this study are included in this published article.

References

[1] Dehner LP. Primitive neuroectodermal tumor and Ewing's-sarcoma. Am J Surg Pathol 1993;17(1):1–13. doi:10.1097/00000478-199301000-00001.

[2] Dehner LP. The evaluation of the diagnosis and understanding of primitive and embryonic neoplasms in children: living through an epoch. Mod Pathol 1998;11(7):689–685.

[3] Li T, Zhang F, Cao Y, Ning S, Bi Y, Xue W, Lu T. [17] Murray FB, Cristina RA, Robert GM. Management of soft tissue sarcoma. New York: Springer. 2013, p. 222.

[4] Shek TWH, Chan GCF, Khong PL, Chung LP, Cheung ANY. Ewing sarcoma and molecular study. Hum Pathol 2001;32(10):1109–1115. doi:10.1053/hupa.2001.28247.

[5] Huang SF, Chiang JH, Jan HC, Chou SJ, Chen TK, Chen TH. Intra-abdominal Ewing's sarcoma: a case report and review of the literature. J Gastrointest Oncol 2011;2:348–353. doi:10.4251/wjgo.v12.i37.6070.

[6] Chen L, Xu Y, Song H, Huang H, Zhou D. A rare entity of primary Ewing sarcoma in kidney. BMC Surg 2020;21(1):280. doi:10.1186/s12893-020-00948-9.

[7] Movahedi-Lankarani S, Ruban RH, Westra WH, Klimstra DS. Primitive neuroectodermal tumors of the pancreas - a report of seven cases of a rare neoplasm. Am J Surg Pathol 2002;26(8):1040–1047. doi:10.1097/00000478-200208000-00009.

[8] Shek TWH, Chan GCF, Khong PL, Chung LP, Cheung ANY. Ewing sarcoma of the small intestine. Pediatr Hematol Oncol 2001;18(3):330–332. doi:10.1097/00000478-200111000-00013.

[9] Camburzali I, Guerra EE, Hilgert HC, Schmitz HJ, Silva VL, Milanli DM, et al. Primary neuroectodermal tumor of the ovary - a report of 25 cases. Am J Surg Pathol 1993;17(8):764–778. doi:10.1097/00000478-199308000-00002.

[10] Ozaki Y, Miura Y, Koganemaru S, Suyama K, Inoshita N, Fuji T, et al. Ewing's sarcoma of the liver with multicellular cystic mass formation: a case report. BMC Cancer 2015;15:16. doi:10.1186/s12885-015-1073-7.

[11] Mani S, Dutta D, De BK. Primitive neuroectodermal tumor of the liver: a case report. J Clin Oncol 2011;39(3):258–262. doi:10.1093/jco/ypu158.

[12] Colovic RB, Gruber NM, Micev MT, Matic SV, Atkinson HDE, Latinić SM. Perigastric extrakeltyal Ewing's sarcoma: a case report. World J Gastroenterol 2009;15(2):247. doi:10.3748/wjg.v15.i2.247.

[13] Welch T, Mechsnerheimer G, Altmann S, Mueller SA, Buecher MW, Schmidt J, et al. Huge primitive neuroectodermal tumor of the pancreas: report of a case and review of the literature. World J Gastroenterol 2006;12(37):6070–6073. doi:10.3748/wjg.v12.i37.6070.

[14] Doi H, Ichikawa S, Hiroaka A, Ichinoyu M, Nakahara H, Ochi H, et al. Primitive neuroectodermal tumor of the pancreas. Intern Med 2009;48(5):329–333. doi:10.2169/internalmedicine.48.1484.

[15] O'Sullivan MJ, Periman EJ, Furman J, Humphrey PA, Dehner LP, Pfeifer JD. Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum Pathol 2001;32(10):1109–1115. doi:10.1053/hupa.2001.29247.

[16] Murray FB, Cristina RA, Robert GM. Management of soft tissue sarcoma. New York: Springer. 2013, p. 222.

Lu T. et al: CT and MRI findings for hepatic Ewing's sarcoma

Author contributions

The hospital board committee provided approval for the procedural application in clinic and case report publication. Written informed consent for publication was obtained from the patient.

Data sharing statement

All data generated or analyzed during this study are included in this published article.

References

[1] Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol 1993;17(1):1–13. doi:10.1097/00000478-199301000-00001.

[2] Dehner LP. The evolution of the diagnosis and understanding of primitive and embryonic neoplasms in children: living through an epoch. Mod Pathol 1998;11(7):689–685.

[3] Li T, Zhang F, Cao Y, Ning S, Bi Y, Xue W, Lu T. [17] Murray FB, Cristina RA, Robert GM. Management of soft tissue sarcoma. New York: Springer. 2013, p. 222.

[4] Shek TWH, Chan GCF, Khong PL, Chung LP, Cheung ANY. Ewing sarcoma of the small intestine. Pediatr Hematol Oncol 2001;18(3):330–332. doi:10.1097/00000478-200111000-00013.

[5] Huang SF, Chiang JH, Jan HC, Chou SJ, Chen TK, Chen TH. Intra-abdominal Ewing's sarcoma. An J Surg Pathol 2011;31(5):377–378. doi:10.1001/ajjp.2011.445-2197.3

[6] Ozaki Y, Miura Y, Koganemaru S, Suyama K, Inoshita N, Fuji T, et al. Ewing's sarcoma of the liver with multicellular cystic mass formation: a case report. BMC Cancer 2015;15:16. doi:10.1186/s12885-015-1073-7.

[7] Mani S, Dutta D, De BK. Primitive neuroectodermal tumor of the liver: a case report. J Clin Oncol 2011;39(3):258–262. doi:10.1093/jco/ypu158.

[8] Colovic RB, Gruber NM, Micev MT, Matic SV, Atkinson HDE, Latinić SM. Perigastric extrakeltyal Ewing's sarcoma: a case report. World J Gastroenterol 2009;15(2):247. doi:10.3748/wjg.v15.i2.247.

[9] Welch T, Mechsnerheimer G, Altmann S, Mueller SA, Buecher MW, Schmidt J, et al. Huge primitive neuroectodermal tumor of the pancreas: report of a case and review of the literature. World J Gastroenterol 2006;12(37):6070–6073. doi:10.3748/wjg.v12.i37.6070.

[10] Doi H, Ichikawa S, Hiroaka A, Ichinoyu M, Nakahara H, Ochi H, et al. Primitive neuroectodermal tumor of the pancreas. Intern Med 2009;48(5):329–333. doi:10.2169/internalmedicine.48.1484.

[11] O'Sullivan MJ, Periman EJ, Furman J, Humphrey PA, Dehner LP, Pfeifer JD. Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum Pathol 2001;32(10):1109–1115. doi:10.1053/hupa.2001.29247.

[12] Murray FB, Cristina RA, Robert GM. Management of soft tissue sarcoma. New York: Springer. 2013, p. 222.

[13] Barnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML. Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with venacaval tumor thrombus. J Urol 2000;164(3 Pt 1):772. doi:10.1016/S0022-5347(00)01900-0.

[14] Marley EF, Liapis H, Humphrey PA, Nadler RB, Siegel CL, Zhu XP, et al. Primitive neuroectodermal tumor of the kidney - another enigma: a pathologic, immunohistochemical, and molecular diagnostic study. Am J Surg Pathol 1997;21(3):354–359. doi:10.1097/00000478-199703000-00013.

[15] Shek TWH, Chan GCF, Khong PL, Chung LP, Cheung ANY. Ewing sarcoma and primitive neuroectodermal tumours in adults: single-centre experience in the Netherlands. Neth J Med 2007;65(4):132–136.